Monoclonal Antibodies (mAbs) remain the largest and most commercially successful product segment, serving as the financial engine for the Biopharmaceuticals Market due to their precise targeting capability against specific disease markers, and their widespread application across oncology, autoimmune disorders, and infectious diseases continues to drive significant market share and substantial...